Home Hot keywords

Search Modes

小提示: 仅限搜索简体中文结果。您可以在设置中指定搜索语言

搜索结果

069 patent
The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid ...
2021年12月1日Arbutus owns the '069 patent directed to “stable nu- cleic acid-lipid particles (SNALP) comprising a nucleic acid. (such as one or more ...
19 页·164 KB
2020年7月23日Arbutus retained all rights to its LNP and conjugate delivery platforms for HBV. The '069 Patent was included in this license agreement between ...
2020年7月28日On July 23, 2020, Arbutus prevailed in Moderna's third IPR challenge to one of its patents, the '069 patent. Given that Moderna's COVID-19 ...
2020年7月28日Moderna's IPR for the '069 patent argues that long before Arbutus' patents, it was well known to use cationic lipids in LNP delivery of mRNA ...
作者:C is positioning its anti-TIGITThe '069 patent is licensed to Genevant Sciences, a maker of LNPs for RNA-based therapeutics, and Arbutus would receive 20% of any revenue ...
2020年8月5日The '069 patent is directed to stable nucleic acid-lipid particles (SNALP), methods of making them and methods of delivering them.
2020年7月23日The '069 patent relates to lipid nanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins.
Patent citations (4)CN101064625A * 2006-04-27 2007-10-31 中兴通讯股份有限公司 一种穿越网络地址翻译网关对用户侧设备进行管理的方法.
Info: Patent citations (9); Cited by (1); Legal events; Similar documents ... CN109274658B * 2018-09-04 2020-11-06 烽火通信科技股份有限公司 基于tr069协议的 ...

Page Navigation

google search trends